InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,058.76
(
0.29%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12469
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Tuesday, 05/31/2011 5:25:21 AM

Tuesday, May 31, 2011 5:25:21 AM

Post# of 80490
Ariad Eagerly Awaits the Big Show, ASCO, To Display Cancer Trial Results

Luke Timmerman 5/31/11

Ariad Pharmaceuticals’ stock has surged 73 percent since New Year’s Day, so you could say CEO Harvey Berger is having a better-than-average year. The Cambridge, MA-based cancer drug developer has seen its market valuation eclipse $1 billion, on a wave of anticipation heading into what could be the most important medical meeting in his company’s 20-year history.

And yet he says he’s still not satisfied.

"My view is that the stock is still way underpriced,” Berger says

My comment:
I tend to agree..

http://www.xconomy.com/boston/2011/05/31/ariad-eagerly-awaits-the-big-show-asco-to-display-cancer-trial-results/
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up